Loading…
Public–private partnerships in translational medicine: Concepts and practical examples
The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships h...
Saved in:
Published in: | Journal of controlled release 2012-07, Vol.161 (2), p.416-421 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3 |
container_end_page | 421 |
container_issue | 2 |
container_start_page | 416 |
container_title | Journal of controlled release |
container_volume | 161 |
creator | Luijten, Peter R. van Dongen, Guus A.M.S. Moonen, Chrit T. Storm, Gert Crommelin, Daan J.A. |
description | The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument.
Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery.
[Display omitted] |
doi_str_mv | 10.1016/j.jconrel.2012.03.012 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1021127849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365912001988</els_id><sourcerecordid>1021127849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</originalsourceid><addsrcrecordid>eNqFkM9O3DAQh62qqCyUR2ibYy8JYzuOnV4qtCp_JCSQKBI3y3EmrVdZJ7W9CG68A2_YJ6nRLlyrOfwO883Y8xHyiUJFgTbHq2plJx9wrBhQVgGvcrwjC6okL-u2Fe_JInOq5I1o98lBjCsAELyWH8g-Y3UjeAsLcne96UZn_z49z8Hdm4TFbELyGOJvN8fC-SIF4-Nokpu8GYs19s46j9-K5eQtzikWxvfFHIxNzmYAH8x6HjF-JHuDGSMe7fKQ3J7--Lk8Ly-vzi6WJ5el5apNZS2NAcVU14OQSgrJeuQgW85lLerGggFOWWfVMKi-hn6wudEJqppOSt52_JB83e6dw_RngzHptYsWx9F4nDZRU2CUMqnqNqNii9owxRhw0PnmtQmPGdIvUvVK76TqF6kauM6R5z7vnth0-f63qVeLGfiyBQYzafMruKhvb_IGAUBlkysT37cEZhX3DoOO1mEW2LuANul-cv_5xD-64ZVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021127849</pqid></control><display><type>article</type><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><source>ScienceDirect Freedom Collection</source><creator>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</creator><creatorcontrib>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</creatorcontrib><description>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument.
Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2012.03.012</identifier><identifier>PMID: 22465390</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; climate ; diagnostic techniques ; Drug Industry ; drugs ; HIFU ; Humans ; Image guided drug delivery ; Magnetic Resonance Imaging ; medicine ; Molecular Imaging ; MRI ; Netherlands ; new products ; PET ; Positron-Emission Tomography ; Public-Private Sector Partnerships ; Public–private partnerships ; technology ; translation (genetics) ; Translational Medical Research ; ultrasonics ; Universities</subject><ispartof>Journal of controlled release, 2012-07, Vol.161 (2), p.416-421</ispartof><rights>2012 Elsevier B.V.</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</citedby><cites>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22465390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luijten, Peter R.</creatorcontrib><creatorcontrib>van Dongen, Guus A.M.S.</creatorcontrib><creatorcontrib>Moonen, Chrit T.</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Crommelin, Daan J.A.</creatorcontrib><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument.
Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery.
[Display omitted]</description><subject>Animals</subject><subject>climate</subject><subject>diagnostic techniques</subject><subject>Drug Industry</subject><subject>drugs</subject><subject>HIFU</subject><subject>Humans</subject><subject>Image guided drug delivery</subject><subject>Magnetic Resonance Imaging</subject><subject>medicine</subject><subject>Molecular Imaging</subject><subject>MRI</subject><subject>Netherlands</subject><subject>new products</subject><subject>PET</subject><subject>Positron-Emission Tomography</subject><subject>Public-Private Sector Partnerships</subject><subject>Public–private partnerships</subject><subject>technology</subject><subject>translation (genetics)</subject><subject>Translational Medical Research</subject><subject>ultrasonics</subject><subject>Universities</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkM9O3DAQh62qqCyUR2ibYy8JYzuOnV4qtCp_JCSQKBI3y3EmrVdZJ7W9CG68A2_YJ6nRLlyrOfwO883Y8xHyiUJFgTbHq2plJx9wrBhQVgGvcrwjC6okL-u2Fe_JInOq5I1o98lBjCsAELyWH8g-Y3UjeAsLcne96UZn_z49z8Hdm4TFbELyGOJvN8fC-SIF4-Nokpu8GYs19s46j9-K5eQtzikWxvfFHIxNzmYAH8x6HjF-JHuDGSMe7fKQ3J7--Lk8Ly-vzi6WJ5el5apNZS2NAcVU14OQSgrJeuQgW85lLerGggFOWWfVMKi-hn6wudEJqppOSt52_JB83e6dw_RngzHptYsWx9F4nDZRU2CUMqnqNqNii9owxRhw0PnmtQmPGdIvUvVK76TqF6kauM6R5z7vnth0-f63qVeLGfiyBQYzafMruKhvb_IGAUBlkysT37cEZhX3DoOO1mEW2LuANul-cv_5xD-64ZVs</recordid><startdate>20120720</startdate><enddate>20120720</enddate><creator>Luijten, Peter R.</creator><creator>van Dongen, Guus A.M.S.</creator><creator>Moonen, Chrit T.</creator><creator>Storm, Gert</creator><creator>Crommelin, Daan J.A.</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120720</creationdate><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><author>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>climate</topic><topic>diagnostic techniques</topic><topic>Drug Industry</topic><topic>drugs</topic><topic>HIFU</topic><topic>Humans</topic><topic>Image guided drug delivery</topic><topic>Magnetic Resonance Imaging</topic><topic>medicine</topic><topic>Molecular Imaging</topic><topic>MRI</topic><topic>Netherlands</topic><topic>new products</topic><topic>PET</topic><topic>Positron-Emission Tomography</topic><topic>Public-Private Sector Partnerships</topic><topic>Public–private partnerships</topic><topic>technology</topic><topic>translation (genetics)</topic><topic>Translational Medical Research</topic><topic>ultrasonics</topic><topic>Universities</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luijten, Peter R.</creatorcontrib><creatorcontrib>van Dongen, Guus A.M.S.</creatorcontrib><creatorcontrib>Moonen, Chrit T.</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Crommelin, Daan J.A.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luijten, Peter R.</au><au>van Dongen, Guus A.M.S.</au><au>Moonen, Chrit T.</au><au>Storm, Gert</au><au>Crommelin, Daan J.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Public–private partnerships in translational medicine: Concepts and practical examples</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2012-07-20</date><risdate>2012</risdate><volume>161</volume><issue>2</issue><spage>416</spage><epage>421</epage><pages>416-421</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument.
Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>22465390</pmid><doi>10.1016/j.jconrel.2012.03.012</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2012-07, Vol.161 (2), p.416-421 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1021127849 |
source | ScienceDirect Freedom Collection |
subjects | Animals climate diagnostic techniques Drug Industry drugs HIFU Humans Image guided drug delivery Magnetic Resonance Imaging medicine Molecular Imaging MRI Netherlands new products PET Positron-Emission Tomography Public-Private Sector Partnerships Public–private partnerships technology translation (genetics) Translational Medical Research ultrasonics Universities |
title | Public–private partnerships in translational medicine: Concepts and practical examples |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A44%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Public%E2%80%93private%20partnerships%20in%20translational%20medicine:%20Concepts%20and%20practical%20examples&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Luijten,%20Peter%20R.&rft.date=2012-07-20&rft.volume=161&rft.issue=2&rft.spage=416&rft.epage=421&rft.pages=416-421&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2012.03.012&rft_dat=%3Cproquest_cross%3E1021127849%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1021127849&rft_id=info:pmid/22465390&rfr_iscdi=true |